dostarlimab

Details

Generic Name:
dostarlimab
Project Status:
Pending
Therapeutic Area:
Endometrial cancer
Manufacturer:
GlaxoSmithKline Inc.
Call for patient/clinician input open:
Brand Name:
Jemperli
Project Line:
Reimbursement Review
Project Number:
PC0381-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​In combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.